bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
All Web sites
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2013: M A M F J
2012: D N O S A J J M

 
  Other news for:
Hepatitis
Viruses
 Resources from HONselect
Treatment for New, Deadly Coronavirus Shows Promise
Researchers report two drugs currently used to treat hepatitis C stopped virus from replicating in lab tests

By Robert Preidt

THURSDAY, April 18 (HealthDay News) -- A treatment for a new coronavirus that has caused 11 deaths, mostly in the Middle East, shows promise in early tests, U.S. government researchers report.

The investigators discovered that a combination of two antiviral drugs -- ribavirin and interferon-alpha 2b -- can stop the so-called nCoV coronavirus from multiplying in laboratory-grown cells. While the results suggest that this drug combination could be used to treat patients infected with nCoV, more research is needed to confirm these early findings.

Both drugs are approved in the United States for treating people with hepatitis C.

The nCoV coronavirus was first identified in Saudi Arabia in September 2012. As of April 16, 2013, there had been 17 reported cases, including 11 deaths. Most cases have occurred in the Middle East.

While the number of cases is small, there has been person-to-person transmission of the nCoV coronavirus in situations where people -- mainly family members -- have had close contact with infected people, the researchers noted in a news release from the U.S. National Institute of Allergy and Infectious Diseases (NIAID).

That, along with the high death rate, led the NIAID researchers to look for treatments. In laboratory tests using cells from two monkey species, the research team found that either ribavirin or interferon-alpha 2b alone could stop nCoV from replicating in the cells.

However, the drug concentrations needed to do this were higher than what is recommended for people. The researchers then combined the two drugs, and found that they were effective at a dose that can be used in people, according to the study in the April 18 issue of the journal Scientific Reports.

More information

The U.S. Centers for Disease Control and Prevention has more about the nCoV coronavirus.

SOURCE: U.S. National Institute of Allergy and Infectious Diseases, news release, April 18, 2013

Health News Copyright © 2013 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=675514

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Therapeutics
Research Personnel
Specialty Chemicals and Products
Hepatitis
Cells
Hepatitis C
Hypersensitivity
Communicable Diseases
Ribavirin
Family
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact